Strategic use of new generation antidepressants for depression

SUN(^_^)D study protocol

Toshi A. Furukawa, Tatsuo Akechi, Shinji Shimodera, Mitsuhiko Yamada, Kazuhira Miki, Norio Watanabe, Masatoshi Inagaki, Naohiro Yonemoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant. Because more than half of the patients with major depression starting treatment do not remit after adequate trial with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the three often recommended second line strategies but we do not know which is better than the others. Moreover, we do not know when to start considering this second line treatment.The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum 1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major depressive episode.Methods: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week 1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3. The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan.Discussion: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments.Trial registration: ClinicalTrials.gov: NCT01109693.

Original languageEnglish
Article number116
JournalTrials
Volume12
DOIs
Publication statusPublished - May 11 2011
Externally publishedYes

Fingerprint

Antidepressive Agents
Depression
Sertraline
Therapeutics
Health
Pragmatic Clinical Trials
Psychopharmacology
Organized Financing
Telephone
Meta-Analysis
Japan
Randomized Controlled Trials

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., ... Yonemoto, N. (2011). Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials, 12, [116]. https://doi.org/10.1186/1745-6215-12-116

Strategic use of new generation antidepressants for depression : SUN(^_^)D study protocol. / Furukawa, Toshi A.; Akechi, Tatsuo; Shimodera, Shinji; Yamada, Mitsuhiko; Miki, Kazuhira; Watanabe, Norio; Inagaki, Masatoshi; Yonemoto, Naohiro.

In: Trials, Vol. 12, 116, 11.05.2011.

Research output: Contribution to journalArticle

Furukawa, TA, Akechi, T, Shimodera, S, Yamada, M, Miki, K, Watanabe, N, Inagaki, M & Yonemoto, N 2011, 'Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol', Trials, vol. 12, 116. https://doi.org/10.1186/1745-6215-12-116
Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N et al. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials. 2011 May 11;12. 116. https://doi.org/10.1186/1745-6215-12-116
Furukawa, Toshi A. ; Akechi, Tatsuo ; Shimodera, Shinji ; Yamada, Mitsuhiko ; Miki, Kazuhira ; Watanabe, Norio ; Inagaki, Masatoshi ; Yonemoto, Naohiro. / Strategic use of new generation antidepressants for depression : SUN(^_^)D study protocol. In: Trials. 2011 ; Vol. 12.
@article{333cdc10c42c4ec6b53211877d2bb784,
title = "Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol",
abstract = "Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant. Because more than half of the patients with major depression starting treatment do not remit after adequate trial with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the three often recommended second line strategies but we do not know which is better than the others. Moreover, we do not know when to start considering this second line treatment.The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum 1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major depressive episode.Methods: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week 1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3. The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan.Discussion: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments.Trial registration: ClinicalTrials.gov: NCT01109693.",
author = "Furukawa, {Toshi A.} and Tatsuo Akechi and Shinji Shimodera and Mitsuhiko Yamada and Kazuhira Miki and Norio Watanabe and Masatoshi Inagaki and Naohiro Yonemoto",
year = "2011",
month = "5",
day = "11",
doi = "10.1186/1745-6215-12-116",
language = "English",
volume = "12",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Strategic use of new generation antidepressants for depression

T2 - SUN(^_^)D study protocol

AU - Furukawa, Toshi A.

AU - Akechi, Tatsuo

AU - Shimodera, Shinji

AU - Yamada, Mitsuhiko

AU - Miki, Kazuhira

AU - Watanabe, Norio

AU - Inagaki, Masatoshi

AU - Yonemoto, Naohiro

PY - 2011/5/11

Y1 - 2011/5/11

N2 - Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant. Because more than half of the patients with major depression starting treatment do not remit after adequate trial with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the three often recommended second line strategies but we do not know which is better than the others. Moreover, we do not know when to start considering this second line treatment.The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum 1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major depressive episode.Methods: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week 1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3. The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan.Discussion: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments.Trial registration: ClinicalTrials.gov: NCT01109693.

AB - Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant. Because more than half of the patients with major depression starting treatment do not remit after adequate trial with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the three often recommended second line strategies but we do not know which is better than the others. Moreover, we do not know when to start considering this second line treatment.The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum 1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major depressive episode.Methods: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week 1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3. The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan.Discussion: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments.Trial registration: ClinicalTrials.gov: NCT01109693.

UR - http://www.scopus.com/inward/record.url?scp=79955777857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955777857&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-12-116

DO - 10.1186/1745-6215-12-116

M3 - Article

VL - 12

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 116

ER -